This study evaluated the associations between genetic proxies of cholesterol-lowering drug targets (HMGCR, PCSK9, and NPC1L1) and the risk of diabetic complications, including nephropathy, retinopathy, and neuropathy. Here, HMGCR is linked to retinal disorder.